Immunohistochemical Assessment of the Peripheral Benzodiazepine Receptor in Breast Cancer and Its Relationship with Survival

Galiègue, Sylvaine; Casellas, Pierre; Kramar, Andrew; Tinel, Norbert; Simony-Lafontaine, Joëlle

doi:10.1158/1078-0432.ccr-03-0988

Cited by 88 publications

(101 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HR associated with Ki-67 positivity in this case) from studies with inherent dissimilarities. The observed disparity among the conclusions of different studies, responsible for the observed heterogeneity, can be quantified by applying Bukholm et al (2003) 147 No Ceccarelli et al (2000) 217 Yes Galiegue et al (2004) 117 No Gasparini et al (1992) 164 Yes Haerslev et al (1996) 487 Yes Jalava et al (2000) 414 No Kroger et al (2006) 157 No Kronblad et al (2006) 377 Yes Lampe et al (1998) 142 Yes Liu et al (2000) 225 Yes Michels et al (2003) 104 No Molino et al (1997) 322 Yes Rudas et al (1994) 184 No Tsutsui et al (2005) 249 Yes Yang et al (2003) 147 No…”

Section: Discussionmentioning

confidence: 99%

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

et al. 2007

View full text Add to dashboard Cite

The Ki-67 antigen is used to evaluate the proliferative activity of breast cancer (BC); however, Ki-67's role as a prognostic marker in BC is still undefined. In order to better define the prognostic value of Ki-67/MIB-1, we performed a meta-analysis of studies that evaluated the impact of Ki-67/MIB-1 on disease-free survival (DFS) and/or on overall survival (OS) in early BC. Sixty-eight studies were identified and 46 studies including 12 155 patients were evaluable for our meta-analysis; 38 studies were evaluable for the aggregation of results for DFS, and 35 studies for OS. Patients were considered to present positive tumours for the expression of Ki-67/MIB-1 according to the cut-off points defined by the authors. Ki-67/MIB-1 positivity is associated with higher probability of relapse in all patients (HR ¼ 1.93 (95% confidence interval (CI): 1.74 -2.14); Po0.001), in node-negative patients (HR ¼ 2.31 (95% CI: 1.83 -2.92); Po0.001) and in node-positive patients (HR ¼ 1.59 (95% CI: 1.35 -1.87); Po0.001). Furthermore, Ki-67/MIB-1 positivity is associated with worse survival in all patients (HR ¼ 1.95 (95% CI: 1.70 -2.24; Po0.001)), node-negative patients (HR ¼ 2.54 (95% CI: 1.65 -3.91); Po0.001) and node-positive patients (HR ¼ 2.33 (95% CI: 1.83 -2.95); Po0.001). Our meta-analysis suggests that Ki-67/ MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early BC.

show abstract

Section: Discussionmentioning

confidence: 99%

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Overexpression of TSPO has also been observed in breast cancer cell lines (139) and in clinical studies (140). In the former, estrogen receptor-negative breast cancer cell lines had significantly higher TSPO expression compared to ER-positive lines and the levels of TSPO were positively correlated with the proliferation marker, Ki-67 (139).…”

Section: Tspo In Cellular and Tissues Pathologymentioning

confidence: 90%

“…This observation was mirrored in the clinical study in which TSPO expression was significantly increased in tumoral versus normal breast cells and TSPO was again correlated with Ki-67 levels. TSPO was anyway never associated with reduced prognosis in the whole patient sample, but in lymph-node negative group of patients, elevated TSPO was linked to a shorter disease-free survival period, indicating that TSPO could be used to identify a higher risk population in this category (140). TSPO is reported overexpressed in oesophageal cancer cells compared to normal oesophageal epithelium (141), as well as in human endometrial carcinoma, where significantly more mitochondrial TSPO was observed in contrast to normal endometrium (142).…”

Section: Tspo In Cellular and Tissues Pathologymentioning

confidence: 95%

TSPO: kaleidoscopic 18-kDa amid biochemical pharmacology, control and targeting of mitochondria

Gatliff

Campanella

2016

Biochemical Journal

View full text Add to dashboard Cite

The 18-kDa translocator protein (TSPO) localizes in the outer mitochondrial membrane (OMM) of cells and is readily up-regulated under various pathological conditions such as cancer, inflammation, mechanical lesions and neurological diseases. Able to bind with high affinity synthetic and endogenous ligands, its core biochemical function resides in the translocation of cholesterol into the mitochondria influencing the subsequent steps of (neuro-)steroid synthesis and systemic endocrine regulation. Over the years, however, TSPO has also been linked to core cellular processes such as apoptosis and autophagy. It interacts and forms complexes with other mitochondrial proteins such as the voltage-dependent anion channel (VDAC) via which signalling and regulatory transduction of these core cellular events may be influenced. Despite nearly 40 years of study, the precise functional role of TSPO beyond cholesterol trafficking remains elusive even though the recent breakthroughs on its high-resolution crystal structure and contribution to quality-control signalling of mitochondria. All this along with a captivating pharmacological profile provides novel opportunities to investigate and understand the significance of this highly conserved protein as well as contribute the development of specific therapeutics as presented and discussed in the present review.

show abstract

“…20,52 In whole-cell assays, specific PK11195 binding can vary more than 20-fold in primary AML cell samples and is frequently higher in AMLs than in normal bone marrow cells (Walter et al 21 and data not shown). Cells from ovary, liver, colon, breast, and brain tumors also express dramatically higher levels of pBR relative to normal cells of the same tissue origin (eg, Galiegue et al 60 ). Because we have shown that increased pBR expression can increase the degree to which PK11195 chemosensitizes transporterdeficient cancer cells, PK11195 binding data may have prognostic value for PK11195 clinical applications aimed at promoting mitochondrial-mediated apoptosis.…”

Section: Discussionmentioning

confidence: 99%

PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism

Walter

Pirga

Cronk

et al. 2005

Blood

View full text Add to dashboard Cite

Immunohistochemical Assessment of the Peripheral Benzodiazepine Receptor in Breast Cancer and Its Relationship with Survival

Abstract: As the axillary lymph node-negative status is generally considered as a good prognosis factor, the high expression of PBR in this patient subgroup may be used to identify a new high risk population, for which a more specific therapy would be beneficial.

Cited by 88 publications

References 20 publications

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

TSPO: kaleidoscopic 18-kDa amid biochemical pharmacology, control and targeting of mitochondria

PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism

Contact Info

Product

Resources

About